Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 23;44(2):582–592. doi: 10.3892/ijmm.2019.4207

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Huang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

ZOL specifically attenuates RANKL-induced NF-κB and JNK signalling. (A) RAW264.7 cells were induced with RANKL for the indicated times following pre-treatment with ZOL (5 µM) for 4 h. Western blot analysis was performed using specific antibodies. The band intensities were quantified using Image J software. The ratios of band intensity of (B) p-IκBα/IκBα, (C) p-p65/p65, (D) p-JNK/JNK, (E) p-p38/p38 and (F) p-ERK/ERK are shown. (G) ZOL inhibited osteoclast differentiation at an early stage. RAW264.7 cells were treated with or without 5 µM ZOL at days 0, 1, 3 and 4. They were subsequently treated with 100 ng/ml RANKL for 5 days, and then subjected to TRAP staining. (H) The number and (I) area of osteoclasts were quantified. ^*P<0.05, ^**P<0.01 vs. the RANKL-only group. TRAP, tartrate-resistant acid phosphatase; ZOL, zoledronic acid; RANKL, receptor activator of nuclear-κB ligand.

ZOL specifically attenuates RANKL-induced NF-κB and JNK signalling. (A) RAW264.7 cells were induced with RANKL for the indicated times following pre-treatment with ZOL (5 µM) for 4 h. Western blot analysis was performed using specific antibodies. The band intensities were quantified using Image J software. The ratios of band intensity of (B) p-IκBα/IκBα, (C) p-p65/p65, (D) p-JNK/JNK, (E) p-p38/p38 and (F) p-ERK/ERK are shown. (G) ZOL inhibited osteoclast differentiation at an early stage. RAW264.7 cells were treated with or without 5 µM ZOL at days 0, 1, 3 and 4. They were subsequently treated with 100 ng/ml RANKL for 5 days, and then subjected to TRAP staining. (H) The number and (I) area of osteoclasts were quantified. ^*P<0.05, ^**P<0.01 vs. the RANKL-only group. TRAP, tartrate-resistant acid phosphatase; ZOL, zoledronic acid; RANKL, receptor activator of nuclear-κB ligand.